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22Objective: Preeclampsia is a complex genetic disease of
pregnancy with a heterogenous presentation, unknown
cause and potential severe outcomes for both mother and
child. Preeclamptic women have increased risk for
atherothrombotic cardiovascular disease. We aimed to
identify heritabilities and phenotypic correlations of
preeclampsia and related conditions in the Norwegian
Preeclampsia Family Biobank.
Methods: By applying a variance components model, a
total of 493 individuals (from 138 families with increased
occurrence of preeclampsia) were classified according to
30 disease-related phenotypes.
Results: Of parous women, 75.7% (263/338) had
experienced preeclampsia and 35.7% of women with and
22.4% without preeclampsia delivered children small for
gestational age (SGA). We identified 11 phenotypes as
heritable. The increased occurrence of preeclampsia was
reflected by the presence [heritability (H2r)¼0.60)] and
severity (H2r¼ 0.15) of preeclampsia and being born in a
preeclamptic pregnancy (H2r¼0.25). Other heritable
phenotypes identified included SGA (H2r¼ 0.40), chronic
hypertension (H2r¼0.57), severity of atherothrombotic
cardiovascular disease (H2r¼ 0.31), BMI (H2r¼ 0.60) and
pulmonary disease (H2r¼ 0.91). The heritable phenotype
preeclampsia overlapped with SGA (P¼ 0.03), whereas
pulmonary disease was phenotypically correlated with
atherothrombotic cardiovascular disease (P< 0.01), SGA
(P¼0.02) and BMI (P¼0.02).
Conclusion: This is the first study identifying the H2r of a
range of health-related conditions in preeclamptic families.
Our study demonstrates how refinement of phenotypes
leads to better H2r estimation and the identification of a
biological relationship between preeclampsia and related
traits.
Keywords: biobank, family cohort, heritability estimate,
phenotypes, phenotypic correlation, phenotyping,
preeclampsia
Abbreviations: aCVD, atherothrombotic cardiovascular
disease; DM2, diabetes mellitus type 2; H2r, heritability;
HELLP, gestational syndrome incorporating haemolysis,
elevated liver enzymes and low platelets; IUGR, intrauterineopyright © European Society of Cardiology. Unau
94 www.jhypertension.comgrowth retardation; MBRN, the Medical Birth Registry of
Norway; SGA, small for gestational ageINTRODUCTIOND
uring the last decade, new clinical and pathophy-
siological insights have revealed that a diagnosis
defined as one clinical disease entity in reality may
encompass a spectrum of related conditions with deviating
pathogenic mechanisms. Accordingly, a need for higher
phenotypic resolution within the field of translational and
genetic research has emerged to improve the screening,
diagnosis and prediction of complex disorders such as
preeclampsia and cardiovascular diseases [1,2]. Classifi-
cation of phenotypes of common diseases with overlapping
biologic mechanisms could further help identify shared
genetic and pathophysiologic causes and phenotype-
specific therapeutic targets.
Preeclampsia is a major cause of morbidity and mortality
of pregnant women and fetuses with 2–8% of all pregnan-
cies affected [3]. There are neither reliable predictive tests
nor effective therapies other than delivery. Preeclampsia
manifests as elevated maternal blood pressure with protei-
nuria in the latter half of pregnancy and presents with
a range of clinical symptoms and signs, includingthorized reproduction of this article is prohibited.
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Heritable preeclampsia-related traitshypertension and proteinuria diagnosed a few days before
spontaneous delivery without maternal discomfort or
detectable influence on the fetus’ well-being, as well as
maternal multiorgan failure with fetal demise [4]. In a
disease so diverse, it is likely that different pathophysiologic
changes underlie the various phenotypic presentations. To
identify functional changes behind specific disease presen-
tations, it is necessary to carefully select the preeclampsia
phenotype to examine. Any pregnancy will cause haemo-
dynamic changes with physiologic increases in the cardi-
ovascular load. Women who develop preeclampsia in
response may be predisposed to react abnormally through-
out life to increased burdens on their cardiovascular system.
These individuals might have higher risk of developing
atherosclerosis, consequently resulting in conditions
encompassed by the term atherothrombotic cardiovascular
diseases (aCVDs). Systematic research has revealed comor-
bidity of preeclampsia and aCVD, identifying women expe-
riencing preeclampsia with a subsequent two to eight-fold
increased risk of developing established risk factors or
confirmed aCVD [5]. The research on preeclampsia and
aCVD has progressed considerably in recent years [5], but
the genetic contribution to the pathophysiology remains
largely unexplained. Stricter phenotypic differentiation of
complex diseases with several, possibly diverging, etiologic
causes is required to gain knowledge on their biologic
background and address possible underlying and interact-
ing disease mechanisms. One way to further refine pheno-
types is by utilization of available information aggregated
in biobanks.
Biobanks are increasingly used in biomedical research as
repositories of biologic specimens associatedwith collected
information regarding health, environment and lifestyle of
included individuals [6]. Family-based biobanks include
families with increased prevalence of the condition of
interest compared with the general population. Unaffected
family members can be used as controls for the affected
relatives as all share a common genetic background and at
least partially comparable exposures to environmental fac-
tors [7].
Here we describe the Norwegian Preeclampsia Family
Biobank and how we have classified individuals in the
cohort according to 30 disease phenotypes. This study aims
to identify the prevalence and heritability (H2r) of detailed
preeclampsia phenotypes and related health conditions.
Detailed phenotyping increases our knowledge on inher-
itance of specific traits and thereby improve the likelihood
of identifying true genetic associations and biologic mech-
anisms defining a phenotype. To improve classification of
diseases and identify possible overlapping disease-related
phenotypes within the collected families, we evaluate the
phenotypic correlation both between different phenotypes
of preeclampsia and between preeclampsia and associated
conditions including aCVD and fetal intrauterine growth
retardation (IUGR).
METHODS
The Norwegian Preeclampsia Family Biobank
The Preeclampsia Family Biobank is a nested cohort of
families with an increased susceptibility for preeclampsia,Copyright © European Society of Cardiology. Unau
Journal of Hypertensiondefined as pairs of either two sisters or a mother and her
daughter wherein both individuals have had preeclampsia.
The Preeclampsia Family Biobank was established during
2002–2012 to address the genetic basis of preeclampsia [8],
and is based on collaboration between the Norwegian
University of Science and Technology, Trondheim, Nor-
way, and five hospitals in Mid and West Norway (Supple-
mentary Figure 1, http://links.lww.com/HJH/A513). The
population in these regions is ethnically uniform, as only
6.9% is of non-white origin, and migration numbers are low
(Statistics Norway, 2012–2013).
For an illustration of the selection of participants, see
Supplementary Figure 2 (http://links.lww.com/HJH/A513).
The Medical Birth Registry of Norway contains information
on all pregnancies and deliveries in Norway since 1967.
Women who through their unique identification numbers
were found to have a first-degree female relative where
both gave birth at one of the participating hospitals
between 1967 and 2005 and had the diagnosis ‘preeclamp-
sia’ in the Medical Birth Registry of Norway were defined as
having a familial predisposition. Medical doctors examined
hospital records to verify the preeclampsia diagnosis of the
1161 identified preeclamptic pregnancies of 1003 women
against the currently used national criteria, reproducible
hypertension with proteinuria [9,10]. Where only one
woman in a pair fulfilled the criteria, or where one woman
of a pair had died or moved to an unknown address, both
women of the pair were excluded from the study.
The 426 women where both women of a pair had valid
preeclampsia diagnoses and where both were alive and
registered with a postal address in Norway at the time of the
study did fulfil the study criteria and were invited to
participate in the study and extend the invitation to all their
relatives above 17 years of age.
During the period 2009–2011, a standardized interview
of all 496 included participants was performed and blood
samples were collected. For each family, a summary ped-
igree was constructed in Cyrillic 2.1.3 (CyrillicSoftware,
Oxfordshire, UK). The assembled information (Supple-
mentary Table 1, http://links.lww.com/HJH/A513) was
deidentified and quality controlled at Haukeland University
Hospital and stored at the Western Norway Regional Health
Authority database. Blood samples were collected in serum
separator, EDTA and Tempus blood RNA stabilizing tubes
(Applied Biosystems, Foster City, California, USA) from 98%
of the participants. All blood subsets were stabilized and
stored at facilities of the HUNT Research Centre and Bio-
bank, Norwegian University of Science and Technology.
The Preeclampsia Family Biobank establishment and
estimation of phenotypic heritabilities have obtained the
required approvals from the Regional Committees for
Medical Research Ethics, the National Data Inspectorate
and the Preeclampsia Family Biobank. All participants gave
their informed consent when enrolled.
Definitions of phenotypes
Preeclampsia has been defined according to international
criteria as hypertension (blood pressure  140/90) with
proteinuria (þ1 of protein on a urine dip-stick or 0.3 g
protein in a 24-h urine collection) measured on at least two
separate occasions [4,8,11]. As illustrated in Table 1,thorized reproduction of this article is prohibited.
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TABLE 1. Definitions of phenotypes in the Norwegian Preeclampsia Family Biobank
Disease phenotype Subgroup Included diagnostic traits
Preeclampsia Moderate HT with proteinuria
Diagnosed gestation 34 weeksþ0 days
Severe BP 160/110 with proteinuria
HT with proteinuria 3g/24 h
Diagnosed <gestation 34 weeksþ0 days
Symptoms, HELLP, eclampsia
Gestational HT BP140/90
SGA offspring <5 percentile
Anamnestic: slow fetal growth/very small child
aCVDa Risk factors Chronic HT
Hypercholesterolemia
Established disease Coronary heart disease: angina pectoris, acute myocardial infarction
Cerebrovascular disease: ischaemic/haemorrhagic stroke
Other peripheral arterial disease: claudicatio intermittens, thrombosis of extremities
Diabetesa Type 1 Insulin demanding
Childhood or teenage onset
Type 2 Diet only, oral antidiabetic medication alone or in combination with insulin. Onset >age 20
Gestational Diabetes developed and diagnosed during pregnancy
Autoimmune/Inflammatory disease Hypothyroidism
Systemic lupus erythematosus, other specified rheumatic disease, psoriasis
Inflammatory bowel disease
Kidney disease Kidney disease Consistent microhaematuria/macrohaematuria, consistent albuminuria
Glomerulonephritis, nephrosis
Kidney transplant, need of dialysis
Pulmonary disease Asthma
COPD
CVD, atherothrombotic cardiovascular disease; BP, blood pressure; COPD, chronic obstructive pulmonary disease; HELLP, gestational syndrome incorporating haemolysis, elevated liver
nzymes and low platelets; HT, hypertension; SGA, small for gestational age.
ntervention (diet or medication) required.
Thomsen et al.a
e
aIpreeclampsia was examined as a binary trait, presence or
absence of the condition (phenotype ‘preeclampsia’).
Preeclampsia was also classified into moderate or severe
preeclampsia according to international guidelines, and we
further created a probable high-severity phenotype includ-
ing eclampsia (seizures); gestational syndrome incorporat-
ing haemolysis, elevated liver enzymes and low platelets
(HELLP; multiorgan failure); and predefined symptoms.
Preeclampsia diagnosed before gestational week 34 was
defined as early preeclampsia and grouped as severe,
whereas preeclampsia diagnosed at later gestations was
categorized as late preeclampsia and classified as moderate.
IUGR is a condition of inappropriately low fetal growth
estimated by transabdominal ultrasound. In lack of serial
ultrasoundmeasurements in this study, small for gestational
age (SGA) was used as proxy for IUGR. The birth weight
centile for each neonate was computed using common
Norwegian unisex reference ranges established for fetal
growth according to the week of pregnancy [12]. For the
estimated due date, we used the date set either according to
an ultrasound scan done before 20 weeks of gestation or,
when lacking, based on last menstrual period. Gestational
week at birth was calculated based on estimated due date.
Neonates were classified as SGA if their birth weight was
under the 5th centile estimated for the week of gestation
when the birth took place.
To be classified with a disease phenotype, the partici-
pant must have stated that he or she had received relevant
treatment by a medical doctor for the disorder. We separ-
ated each disease modality into several main phenotypes
and phenotypic subgroups as defined in Table 1. The
conditions included in the term aCVD were divided intoCopyright © European Society of Cardiology. Unauthorized reproduction of this article is prohibite
2296 www.jhypertension.com Volume 33  Number 11  November 2015treated risk factors for aCVD and established (meaning
current or previously treated) aCVD. Established aCVD
included coronary heart disease, cerebrovascular disease
and other peripheral arterial disease. Diabetes was pheno-
typed into diabetes mellitus type 1, type 2 (DM2) and
gestational diabetes. The registered inflammatory diseases
included hypothyroidism, systemic lupus erythematosus,
rheumatic disease, psoriasis, inflammatory bowel disease
and the category ‘other specified inflammatory diseases’.
Kidney diseases included glomerulonephritis, nephrosis,
consistent microhaematuria or macrohaematuria, need of
dialysis, consistent albuminuria and kidney transplantation.
Pulmonary diseases encompassed asthma and chronic
obstructive pulmonary disease.
The severity scores for preeclampsia and aCVD are
constructed scores (Supplementary Table 2, http://links.
lww.com/HJH/A513), consisting of grouped variables
with scores between 0 and 5 and therefore analyzed as
quantitative phenotypes. To estimate severity of pre-
eclampsia for each parous woman, all preeclampsia
phenotypes were assigned a value of zero (not present),
one (gestational hypertension), two (moderate disease),
four (severe disease) or five (very severe disease; symp-
toms of preeclampsia, multiorgan failure incorporated by
the HELLP syndrome or eclampsia) [11,13]. All women
were designated a score of disease severity correlating to
their sum of the given values, multiplied with her affected
births and then divided by her nonaffected births. To
score the severity of aCVD for each individual, we des-
ignated each aCVD phenotype with a value of zero
(absence of phenotype), one (aCVD risk factors) or
two (established aCVD). For each participant, an aCVDd.
Heritable preeclampsia-related traitsseverity score was calculated by adding the values for
each aCVD phenotype.
Heritability
Differences in phenotypic presentation between individ-
uals could be caused by variation in genotype or environ-
ment, or combinations of these. The general term
‘heritability’ describes to which amount genes influence
the expression of a phenotype, and H2r estimates the
relative contribution of genetic factors to the expression
of a phenotype in a specific population, not if a trait is
genetic. H2r is an estimate of genotypic and phenotypic
variance within a population, and not an estimate calcu-
lated for individuals.
The correlation between two phenotypes (rP) is pre-
sumed to reflect an association between the two traits and
indicate functional relationship. Both genetic and environ-
mental effects are included in phenotypic correlation esti-
mates [14].Statistical analysis
The computer program SOLAR version 7.2.0 was employed
to estimate and test the significance of heritabilities for
quantitative phenotypes and disease endpoints using the
relevant polygenic commands [15]. Covariates included
were age and sex of the participant, and the age–sex
interactions along with a weighting factor calculated
according to preeclampsia status and assigned each indi-
vidual to correct for the ascertainment bias created by the
inclusion criteria of the cohort. Owing to the potential
effects of kurtosis in variance components models, the
quantitative phenotypes with high residual kurtosis were
normalized using an inverse Gaussian transformation.
Analysis of disease endpoints as discrete binary traits was
performed using a liability threshold model in SOLAR. This
model employs probit-regression for the mean effect com-
ponent and a standard random effects variance component
model for the residual additive genetic component of
variance [14,15].
The phenotypes exhibiting significant H2r were cross-
examined in pairs for phenotypic correlations, using a
likelihood-ratio test that explicitly allows for nonindepend-
ence among related individuals [14,15]. The covariates
established as significant in the H2r estimation of a specific
trait were included in all further calculations involving
that phenotype.RESULTS
Descriptive characteristics
The Preeclampsia Family Biobank includes 138 pedigrees
with a total of 496 individuals (71.4% women). The cohort
contains 102 pairs of women (30 mother–daughter and 72
sister–sister pairs) with verified diagnoses, and in addition
35 women who fulfil the criteria of inclusion but where the
affected first-degree relative was unwilling or unable to
participate [8,10]. The families of these 35 women were
incorporated in the H2r analyses if any other close family
members participated, such as partners or female relatives
with healthy pregnancies or without verified preeclampsiaCopyright © European Society of Cardiology. Unau
Journal of Hypertensiondiagnosis. Descriptive characteristics of the cohort (Supple-
mentary Table 3, http://links.lww.com/HJH/A513) include
information on women who have given birth at least
once (parous) or never (nulliparous), and according to
preeclampsia status where relevant. As the participants
in the cohort are related, subgroups have not been stat-
istically compared according to sex, parity or preeclampsia
status. The mean age at inclusion was 46.8 (standard
deviation 13.4) years for the whole cohort, whereas for
nulliparous women (n¼ 14), the mean age was 25.7
(standard deviation 9.5) years. Mean BMI was 27.1 for all
participants. For men, parous women and nulliparous
women, mean waist circumference was 98.4, 90.7 and
84.5 cm, respectively. Among parous women, the median
number of births was 3.0, ranging from one to eight births,
and the median number of preeclamptic pregnancies were
1.5 (span 0–5).
The 263 women recorded with preeclampsia include the
women primarily invited to the study who had had their
preeclampsia diagnosis verified through medical records,
as well as female relatives reporting in interviews to have
experienced the disease. Of the 263 preeclamptic women,
81% had the disease in their first pregnancy (Supplementary
Table 4, http://links.lww.com/HJH/A513). In 50% of
women with an affected first pregnancy, preeclampsia
did not recur in another pregnancy, whereas 27% experi-
enced preeclampsia in all their pregnancies (data not
shown). The preeclamptic women in the cohort with severe
disease phenotype experienced severe preeclampsia in the
form of early preeclampsia (26.2%), preeclampsia with
severe hypertension (36.1%) and preeclampsia with severe
proteinuria (3.8%). Approximately 36% of preeclamptic
women and 22.4% of women with pregnancies defined
as nonpreeclamptic gave birth to a SGA neonate (Supple-
mentary Table 4, http://links.lww.com/HJH/A513).
Of the relevant disease phenotypes examined, the
percentages for chronic hypertension and for aCVD were
fairly consistent across all groups except for the nulliparous
women, wherein only few individuals were affected
(Supplementary Table 5, http://links.lww.com/HJH/A513).
The overall prevalence of DM2, the aCVD phenotypes
coronary heart disease (myocardial infarction or unspeci-
fied angina pectoris) and cerebrovascular disease (ischae-
mic or haemorrhagic stroke) were 5.8, 4.5, and 2.3%,
respectively, with a higher proportion of males affected.
Pulmonary diseases were relatively evenly presented in all
subgroups, ranging from 12.8 (men) to 15.5% (parous
women without preeclampsia). Autoimmune diseases
were present in 12.1% of the total cohort and in 13.3%
of the participating women.
Heritability
Table 2 presents the selected phenotypes of preeclampsia
and relevant diseases with significant H2r estimates. For the
complete list of traits examined, see Supplementary Table 6
(http://links.lww.com/HJH/A513). Preeclampsia showed
an overall H2r of 0.60 (P¼ 0.03). The estimated genetic
effects on phenotypic variance ranged from 15.1% (disease
severity of preeclampsia, P¼ 0.03) to 91.0% (pulmonary
disease, P¼ 0.0002). The increased susceptibility of pree-
clampsia in the cohort was supported by significant H2rthorized reproduction of this article is prohibited.
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TABLE 2. Phenotypic traits with significant heritability
Phenotype H2r P value SE
Preeclampsia 0.600 0.033 0.309
Total number of birthsa 0.195 0.029 0.112
Given birth to SGA neonate 0.404 0.012 0.290
Diabetes mellitus type 2 0.568 0.030 0.309
Severity of preeclampsiaa 0.151 0.034 0.088
Chronic hypertension 0.569 0.0061 0.235
Severity of aCVD 0.314 0.0046 0.126
Born in a preeclamptic pregnancy 0.252 0.011 0.117
Pulmonary disease 0.909 0.0002 0.232
BMI 0.603 5.9610-10 0.096
Waist circumferencea 0.575 1.6610-8 0.098
aCVD, atherothrombotic cardiovascular disease; SE, standard error; SGA, small for
gestational age.
aThe quantitative phenotype has been inverse normalized.
P<0.05.
P<0.01.
P<0.001.
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Thomsen et al.estimates of preeclampsia, disease severity of preeclampsia
and having been born in a preeclamptic pregnancy (H2r
0.25, P¼ 0.01). Several other assessed phenotypes were
shown to be heritable in a variance component model
including the predefined covariates (Table 2): chronic
hypertension (H2r 0.57, P¼ 0.006), giving birth to neonates
SGA (H2r 0.40, P¼ 0.01), total number of births (H2r 0.20,
P¼ 0.03) and DM2 (H2r 0.57, P¼ 0.03). Some phenotypes
had high residual kurtosis reflecting that a larger amount of
the variability in the cohort was caused by few extreme
differences from the mean. After normalization of the trait
distribution in the cohort, the following phenotypes also
had significant H2r estimates and normal residuals: disease
severity of preeclampsia, BMI (H2r 0.60, P¼ 6.0 1010),
severity of aCVD (H2r 0.31, P¼ 0.005) and waist circum-
ference (H2r 0.58, P¼ 1.7 108). For the other pheno-
types examined (Supplementary Table 6, http://links.lww.
com/HJH/A513), there were either no significant H2r ident-
ified or the residual kurtosis was too high to be corrected in
the analyses.
Phenotypic correlations
Paired phenotypes with significant phenotypic correlations
(rP) are presented in Table 3. Possible pleiotropy was
demonstrated by the positive phenotypic correlations
between preeclampsia status and how many times a
woman gave birth (19.5%, P< 0.01), as well as between
preeclampsia and giving birth to a SGA child (26.2%,
P¼ 0.03). BMI exhibited positive correlations to chronic
hypertension (26.9%, P< 0.01), severity of aCVD (20.5%,
P< 0.01), DM2 (27.3%, P< 0.01), waist circumference
(57.5%, P< 0.01) and pulmonary disease (17.2%,
P¼ 0.02). Development of pulmonary disease was posi-
tively correlated to the severity of aCVD (18.8%, P< 0.01)
and negatively correlated with giving birth to children SGA
(25.4%, P¼ 0.02). No significant phenotypic correlations
were identified for the other phenotypes examined (data
not given).
DISCUSSION
This is a phenotypic description of the Preeclampsia Family
Biobank, outlining the phenotypic criteria utilized and howCopyright © European Society of Cardiology. Unauthorized reproduction of this article is prohibite
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Heritable preeclampsia-related traitsseveral examined traits are heritable and phenotypically
correlated. To our knowledge, this is the first family study
to examine the presence and H2r of defined phenotypes
of preeclampsia and combine these with conditions such
as aCVD, diabetes and pulmonary disease. The study
demonstrates that preeclampsia, chronic hypertension,
aCVD, DM2, SGA and pulmonary disease are heritable in
the cohort and identifies phenotypic correlations between
these heritable traits.
The purpose of the Preeclampsia Family Biobank was to
establish a resource for investigation of the genetic back-
ground of preeclampsia [8]. Careful definition and selection
of phenotypes for genetic studies can improve identifi-
cation of noneligible subsets, include less heterogeneous
phenotypes and select suitable controls. The family study
design was chosen to minimize the effects of population
heterogeneity, promote discovery of parent-of-origin
effects and identification of quantitative trait loci, and
estimate the H2r of disease-specific traits [7]. Of other
identified family-based cohorts based on preeclampsia, five
studies are corresponding most closely to ours [16–20].
These five studies all focus on the genetics of preeclampsia
but neither examined other disease phenotypes nor inves-
tigated the preeclampsia phenotype in detail except for
inclusion of HELLP in the Dutch study [19]. The results of
our study support presence of a genetic cause of pre-
eclampsia and the theories of how different complex dis-
eases are influenced by partly shared inherited genetic
pathways.
A relation between preeclampsia and aCVD was
described as early as in 1927 [21] and since then an increas-
ing number of studies have identified women with pree-
clamptic pregnancies to have an enhanced risk of
subsequently developing aCVD, hypertension and DM2
[5,22,23]. Our results confirm the association between pre-
eclampsia and aCVD. Familial clustering of aCVD and aCVD
risk factors, including DM2, and H2r of delivering SGA
neonates and pulmonary disease in families have been
indicated repeatedly [24–27]. The novel discovery in our
study is that hypertension, aCVD, DM2, giving birth to
children SGA and pulmonary disease are all heritable in
a family cohort based on a different disease, preeclampsia.
To our knowledge, this is further the first study including
both female and male relatives in the H2r estimates for
preeclampsia and delivery of SGA neonates. Obtaining a
more comprehensive paternal family information enable us
to include the male contribution to development of the
conditions in the investigation of trait H2r.
A normal pregnancy augments cardiovascular demands
and an increased activation of the immune system. If a
woman has a preeclamptic pregnancy, the stress-test theory
hypothesizes that she is inclined to react abnormally
to increased metabolic and cardiovascular stress. Con-
sequently, preeclampsia indicates that she will be suscept-
ible to developing aCVD in response to metabolic and
cardiovascular changes later in life [28]. The identification
of preeclampsia, chronic hypertension, aCVD and DM2 as
heritable and with a partly overlapping H2r in the cohort
supports the stress-test hypothesis. The lack of significant
results concerning other aCVD traits examined may in part
be due to participant numbers and interfamily variations.Copyright © European Society of Cardiology. Unau
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nation why several aCVD phenotypes did not seem herit-
able. The prevalence of chronic hypertension (26.8%),
aCVD (35.3%) and DM2 (5.8%) in the cohort is consistent
with general prevalence estimates in the adult population in
developed countries [29–31]. Despite compatible numbers,
this might not represent the true prevalence of aCVD in the
families. The younger participants from the second and
third generations may not have developed established
aCVD, conditions diagnosed more prevalently with increas-
ing age [31,32], but rather display the risk factors for
the disorder.
An association between preeclampsia and giving birth to
neonates SGA has been identified through pathophysio-
logical and epidemiological research [33–35]. This is the
first report presenting H2r estimates of SGA and a positive
phenotypic correlation between preeclampsia and SGA in a
family-based study. In the cohort, the SGA phenotype is not
restricted to the preeclamptic women as women without
preeclampsia also present with a much higher proportion
of small neonates (22.4%) than the 2.0–11.8% expected
from population studies [33,36]. We believe the phenotypic
clustering of SGA in all the parous women to indicate SGA
as an important trait to consider in future studies. Although
we do observe a trend indicating an inverse phenotypic
correlation between height and giving birth to SGA children
(data not shown), the mean height of women, both with
and without preeclampsia, was in accordance with the
mean age-related height for Norwegian women (Statistics
Norway 2012–2013) [37]. The 26.2% positive correlation
identified between presence of preeclampsia and SGA is
comparable with estimates from two large birth cohorts
[33,35]. Earlier studies have identified 27–57% of pregnan-
cies with early onset of preeclampsia (<gestational week
34) and 18–18.3% of late onset (>gestational week 34) to be
associated with birth of a neonate SGA. Unlike these
reports, we could not identify any phenotypic correlation
between SGA and different subgroups of the preeclampsia
phenotype. Too few individuals with any preeclampsia
subtype combined with large interfamilial variation in phe-
notype presentation in our cohort may partly explain
the differences.
For the very first time, pulmonary diseases are identified
as heritable in a cohort based on preeclampsia. The genetic
background of conditions included in the phenotype pul-
monary disease is illustrated by their accumulation in
families [27,38]. Although the H2r estimates in this study
are noticeably high (90.9%), they are comparable to herit-
abilities of 53–92% reported for studies on asthma [38]. The
overlap in phenotypic H2r estimates found for pulmonary
diseases and aCVD, DM2, BMI and waist circumference are
in accordance with previously demonstrated phenotypic
associations [39,40]. Several previous studies have ident-
ified an increased risk in asthmatic patients both for the
development of preeclampsia and for having SGA children,
with higher risk estimates for women with severe asthma
[41,42]. Contrary to this, our results show a negative cor-
relation between pulmonary diseases and giving birth to
neonates SGA. It is possible that the genes that influence
expression of the corresponding traits participate in the
same genetic pathway and tend to be inherited together.thorized reproduction of this article is prohibited.
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anisms and expression of each phenotype may be influ-
enced by different genes of the same pathway.
There are several strengths to this study. Themultigenera-
tional family cohort is selected from a general population
covering all potential candidates from four out of 20
Norwegian counties, and based on a nationwide compul-
sory birth registry. Linking of unique identification num-
bers to identify the female family relations ensure the
biologic relationship of the invited participants. As the
preeclamptic women all have validated preeclampsia diag-
nosis and we have information from medical records as
well as from interviews of participants, the likelihood of
including true-positive cases in the cohort is increased. In a
preeclampsia research setting, we have established a rela-
tively large biobank that contains more affected families
and which we believe is better characterized than other
family cohorts of this type. Through the combination of
genetic homogeneity, strictly defined phenotypes and
examination of preeclampsia, risk factors and related con-
ditions during pregnancy and later in life, the Preeclampsia
Family Biobank constitutes a unique setting for examin-
ation of geneticH2r of diseases and for correlation between
the defined phenotypes.
One of the main weaknesses of this study is that despite
being the second largest study of its type, the cohort size is
still relatively small. The size of the study, with further
reduction of sample numbers in the phenotypic subsets,
could be a reason why this study did not identify a genet-
ically heritable component of several preeclampsia
phenotypes. Furthermore, the study size could cause a
disproportionally increased effect on the estimates of
H2r as each family and participant may have a relatively
high impact on the result. Although populations may differ
in which genetic changes underlie the disease, the ident-
ified H2r of preeclampsia in our study is comparable to
results from twin studies [43], which supports our esti-
mates. As H2r is largely a component of the population
being studied, presumably a larger sample size could lead
to reduced standard errors for the examined phenotypes
and thereby more robust results. Part of the collected
information is based on interviews and self-reported data,
a research setting associated with decreased diagnostic
validity and recall bias. We have required information
on relevant medical treatment instituted by a physician
for validation and use of the given diagnoses in our
analysis. One potential bias in the study with regard to
the potential H2r of preeclampsia was introduced as the
families included in the studywere assumed to be enriched
for preeclampsia. This bias has been corrected for by
including a calculated weighting for preeclampsia in
all analyses.
Novel in this study is the identification of overlapping
H2r for several phenotypes in a family cohort. The con-
ditions examined, preeclampsia, SGA, aCVD and pulmon-
ary disease, share risk factors, and studies on the separate
conditions have demonstrated that presence of the disorder
of interest increases the risk of developing another of the
diseases [23,24,40,44,45]. Furthermore, pathologic mechan-
isms like endothelial dysfunction and inflammation influ-
ence disease development of all the disorders [34,46,47].Copyright © European Society of Cardiology. Unau
2300 www.jhypertension.comThe overlap in phenotypic H2r discovered in this study
indicates shared biological processes for all of these
traits.
This study demonstrates a thorough phenotyping of a
family-based preeclampsia cohort with estimation of her-
itable phenotypes. The study supports a genetic cause
of preeclampsia. For the first time, phenotypic H2r of
preeclampsia-related traits has been estimated in pre-
eclamptic families, identifying several heritable traits
including SGA, aCVD, chronic hypertension and pulmon-
ary disease. The phenotypic correlations identified indicate
that pathophysiologic mechanisms shared by the examined
phenotypes could be in part caused by identical or corre-
sponding genetic pathways. The results constitute a solid
basis for further research on causative genetic mechanisms
of development of preeclampsia and shared pathophysio-
logic changes between preeclampsia and the related
disease phenotypes.ACKNOWLEDGEMENTS
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This report originates from the Norwegian Preeclampsia
Family Biobank, and describes some early phenotypic data
in respect of a cohort of 496 individuals identified as having a
familial pattern of preeclampsia (PE) from the NorwegianBirth registry between 1967 and 2005. The main conclusions
are that in this cohort, PE, chronic hypertension, atheroscler-
otic cardiovascular diseases, type 2 diabetes, the delivery of
small for dates infants, and pulmonary disease are heritable
and that there are significant correlations between these
traits. The strengths of this study lie principally in the careful
and detailed phenotyping of PE. This is not an easily definedthorized reproduction of this article is prohibited.
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Thomsen et al.entity, but a complex condition with protean manifestations
and a dynamic mode of presentation. Here the authors
attempt to characterise the condition in its various manifes-
tations and to explore associations between these pheno-
types, the extent towhich these areheritable, and linkswith a
number of other phenotypes of birth circumstances and
subsequent adult diseases. The main new findings in theirCopyright © European Society of Cardiology. Unau
2302 www.jhypertension.comstudy are the heritability of pulmonary disease (asthma and
COPD) in this cohort based on selection by PE, and the
overlapping heritability of several other of the phenotypes
identified. The main weakness, so common in many studies
in obstetrics, is the relatively small number of patients
included. The observations may also be relevant only to a
relatively homogeneous Norwegian cohort.thorized reproduction of this article is prohibited.
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